SCHEMBL17740185

SCHEMBL17740185

CCCNC(=O)CON=C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MCL1 Q07820 1/20 0.41
HPGD P15428 1/20 0.39
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 2/20 0.35
GAA P10253 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19704261 0.87 FAAH (0.60) FAAHL3MBTL1LMNASMN1; SMN2MEN1
SCHEMBL6980315 0.85 LMNA (0.41) FAAHL3MBTL1LMNASMN1; SMN2HPGD
SCHEMBL13934654 0.84 LMNA (0.47) FAAHL3MBTL1LMNASMN1; SMN2MCL1
SCHEMBL19704172 0.83 MCL1 (0.40) FAAHL3MBTL1LMNASMN1; SMN2MCL1
SCHEMBL19704169 0.81 CASP2 (0.39) FAAHMCL1GAAMMP1MMP2
SCHEMBL19704366 0.80 CASP2 (0.38) FAAHL3MBTL1LMNASMN1; SMN2MCL1
SCHEMBL6979761 0.80 LGALS1 (0.44) L3MBTL1LMNASMN1; SMN2HPGDTSHR
SCHEMBL19703621 0.79 FAAH (0.45) FAAHTSHR
SCHEMBL19703619 0.79 FAAH (0.45) FAAHTSHR
SCHEMBL17740102 0.78 FAAH (0.47) FAAHGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-12-14 US disclosed
WO-2016071856-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE NOVARTIS AG (CH) 2016-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355731-A1 AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE RNGTT, RNASE1, RNMT FAAH 3895/4885L3MBTL1 1981/4885LMNA 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.